Inhibrx Biosciences (INBX) Capital Expenditures (2023 - 2025)
Inhibrx Biosciences' (INBX) quarterly Capital Expenditures came in at $31000.0 in Q3 2025, down 99.07% year-on-year from $3.3 million in Q3 2024, and up 247.62% on a QoQ basis from -$21000.0 in Q2 2025.
Inhibrx Biosciences (INBX) Capital Expenditures (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 3 years of Capital Expenditures data on file, last reported at $31000.0 in Q3 2025.
- On a quarterly basis, Capital Expenditures fell 99.07% year-over-year to $31000.0 in Q3 2025; TTM through Dec 2025 was $31000.0, a 98.81% decrease from a year earlier, with the FY2025 full-year figure at $31000.0, down 98.81% from the prior year.
- Capital Expenditures for Q3 2025 stood at $31000.0, up from -$21000.0 in the prior quarter.
- Over the last five years, Capital Expenditures for INBX reached as high as $3.4 million in Q4 2023 and fell as low as -$951000.0 in Q4 2024.
- Historically, Capital Expenditures has averaged $802333.3 across 3 years, with a median of $31000.0 in 2025.
- On a YoY basis, Capital Expenditures climbed as much as 190.27% in 2024 and fell as far as 127.63% in 2024.
- Year by year, Capital Expenditures stood at $3.4 million in 2023, then slumped by 127.63% to -$951000.0 in 2024, then surged by 103.26% to $31000.0 in 2025.
- Per Business Quant data, the three most recent Capital Expenditures figures were $31000.0 in Q3 2025, -$21000.0 in Q2 2025, and $21000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Inhibrx Biosciences | 1.32 Bn | 1.32 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 31,000.00 |
| Sep 30, 2025 | 31,000.00 |
| Jun 30, 2025 | -21,000.00 |
| Jun 30, 2025 | -21,000.00 |
| Mar 31, 2025 | 21,000.00 |
| Mar 31, 2025 | 21,000.00 |
| Dec 31, 2024 | -951,000.00 |
| Dec 31, 2024 | -951,000.00 |
| Sep 30, 2024 | 3.34 Mn |
| Sep 30, 2024 | 3.34 Mn |
| Jun 30, 2024 | -100,000.00 |
| Jun 30, 2024 | -100,000.00 |
| Mar 31, 2024 | 307,000.00 |
| Mar 31, 2024 | 307,000.00 |
| Dec 31, 2023 | 3.44 Mn |
| Dec 31, 2023 | 3.44 Mn |
| Sep 30, 2023 | 1.15 Mn |
| Sep 30, 2023 | 1.15 Mn |